Stockscreener 앱 받기
10.54
18.04%
-2.32
시장 영업 전:
11.93
1.39
+13.19%
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Aardvark Therapeutics Inc’s Market Journey: Closing Strong at 7.79, Up 6.86 - DWinneX
Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% – What’s Next? - Defense World
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics Inc. (AARD) reports earnings - qz.com
Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00 - Defense World
BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks
BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com Australia
Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha
Aardvark Therapeutics, Inc.’s Quiet Period Will End on March 25th (NASDAQ:AARD) - Defense World
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World
BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World
BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com
RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa
Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Morgan Stanley Initiates Aardvark Therapeutics at Overweight -March 10, 2025 at 08:13 am EDT - Marketscreener.com
Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target -March 10, 2025 at 08:03 am EDT - Marketscreener.com
BofA sets Aardvark Therapeutics stock with $22 target - Investing.com India
RBC Initiates Aardvark Therapeutics at Outperform With $21 Price Target, Speculative Risk Qualifier - Marketscreener.com
Morgan Stanley sets Aardvark stock target at $29, rating Overweight By Investing.com - Investing.com South Africa
Morgan Stanley sets Aardvark stock target at $29, rating Overweight - Investing.com
San Diego had its first biotech IPO of 2025. Are more on the way? - MSN
Aardvark Therapeutics’ $94.2 Million Initial Public Offering - Global Legal Chronicle
Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Big Moves: Major Stakeholders Invest Heavily in Aardvark Therapeutics - TipRanks
Autism Spectrum Disorder Treatment Market Size is expected - openPR
Aardvark therapeutics sees $20m stock purchase by Decheng capital - Investing.com India
0.39%
3.66%
자본화:
|
볼륨(24시간):